SRDX - Surmodics, Inc.
58.70 0.00 (0.00%)
After hours: 4:34PM EST
| Previous Close | 58.54 |
| Open | 59.50 |
| Bid | 58.55 x 800 |
| Ask | 83.00 x 1000 |
| Day's Range | 58.41 - 60.85 |
| 52 Week Range | 25.00 - 82.35 |
| Volume | 58,111 |
| Avg. Volume | 95,969 |
| Market Cap | 786.463M |
| Beta (3Y Monthly) | 1.18 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.34 |
| Earnings Date | Nov 14, 2017 - Nov 20, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 86.00 |
- Zacks•9 hours ago
CVS Health Aetna Synergy Impressive, PBM Selling Season Solid
CVS Health (CVS) estimates a $750-million earning from near-term synergies with low- to mid-single digit addition in the second year after the closure of Aetna transaction.
- Zacks•9 hours ago
STERIS Rides on Favorable Industry Trends, Rivalry a Concern
STERIS (STE) is currently displaying strong top-line growth on encouraging market trends along with a new product and service portfolio.
- Zacks•10 hours ago
NuVasive's Monolith Corpectomy System Ok'd for Expanded Use
NuVasive's (NUVA) latest FDA 510 (k) clearance receipt is expected to augment customer base and market reach.
- Zacks•yesterday
Hologic Unveils Omni Hysteroscope, Boosts GYN Surgical Arm
Hologic (HOLX) highlights that a direct visualization of the uterine cavity in women with abnormal uterine bleeding will set a benchmark for the medical test.
- Zacks•yesterday
Hill-Rom Adds New Capabilities to Centrella Smart+ Beds
Hill-Rom (HRC) stays focused on expansion through product development. The latest move is expected to boost the top-line results of the company.
- Zacks•yesterday
Varian Medical ProBeam-Equipped Emory Center Opens in Georgia
Varian Medical's (VAR) flagship ProBeam system has lucrative prospects.
- Zacks•yesterday
Here's Why You Should Buy Myriad Genetics (MYGN) Stock Now
Myriad Genetics (MYGN) see strong testing volumes from new products.
- Zacks•2 days ago
Baxter & EFCNI Collaborate to Improve Care for Preterm Born
Baxter's (BAX) latest move is likely to increase the use of Baxter's Numeta G13E triple-chamber PN product.
- Zacks•2 days ago
Here's Why You Should Invest in athenahealth (ATHN) Now
A strong guidance and focus on big data-based health records system make athenahealth (ATHN) a solid investment pick.
- Zacks•2 days ago
Illumina (ILMN) Takes Part in NIH Program With Genotype Launch
The new Infinium Global Diversity Array of Illumina (ILMN) will process up to 1 million cost-free samples to the three genome centers.
- Zacks•6 days ago
Quest Diagnostics Rides on Product Launches, Strategic Deals
Quest Diagnostics' (DGX) consistent efforts to refocus on core diagnostic information services business and disciplined capital deployment buoy optimism on the stock.
- Zacks•6 days ago
STERIS (STE) Dips on New Restructuring Plan, Layoff Decision
STERIS (STE) aims to stop the production of the worst-hit products and move toward the existing manufacturing operations by fiscal 2020.
- Zacks•6 days ago
Here's Why You Should Invest in Chemed (CHE) Stock Right Now
Chemed's (CHE) subsidiaries continue to register strong sales.
- Zacks•6 days ago
ResMed to Buy Propeller Health, Widens Respiratory Care Suite
Post the acquisition, Propeller will continue to operate as an independent entity within ResMed's (RMD) Respiratory Care suite.
- Zacks•7 days ago
Chemed Grows on Robust VITAS & Roto-Rooter Despite Headwinds
Chemed's (CHE) Roto-Rooter business is showing a marked improvement on solid segmental performances at the core plumbing and drain cleaning service plus a strong uptick in water restoration.
- Zacks•8 days ago
Genomic Health (GHDX), BioCartis Extend Deal to Urology
The alliance intends to develop an in vitro diagnostic (IVD) version of the Oncotype DX Genomic Prostate Score (GPS) test of Genomic Health (GHDX) on Biocartis' proprietary Idylla platform.
- Zacks•8 days ago
Zimmer Biomet Rides on New Operational Plan Amid Several Woes
In order to tackle several near-term concerns, Zimmer Biomet (ZBH) of late begins to review its 2018 operating plan to clearly define its go-forward strategies in a number of thrust areas.
- Zacks•9 days ago
LabCorp (LH) Stock Declines 10% on Lowered 2018 Guidance
Lower-than-expected volume expansion within LabCorp Diagnostics, which is also likely to persist for the rest of the year, forces LabCorp (LH) to slash its full-year guidance.
- Zacks•9 days ago
Here's Why You Should Invest in Omnicell (OMCL) Stock Now
Omnicell (OMCL) continues to witness strong conversion wins for new XT series.
- GuruFocus.com•12 days ago
Surmodics Inc (SRDX) Files 10-K for the Fiscal Year Ended on September 30, 2018
Surmodics Inc is a provider of surface modification and in vitro diagnostic technologies to the healthcare industry. Warning! GuruFocus has detected 1 Warning Sign with SRDX. For the last quarter Surmodics Inc reported a revenue of $23.0 million, compared with the revenue of $20.06 million during the same period a year ago.
- Zacks•12 days ago
CVS Health Closes Aetna Deal, Focuses More on Pharmacy Wing
The joint entity of CVS Health (CVS) and Aetna will provide customers with the powerful health resources of the former and the latter's network of providers for quality care.
- Zacks•12 days ago
Here's Why You Should Invest in Surmodics (SRDX) Right Now
A solid fiscal fourth quarter and lucrative IVD prospects make Surmodics (SRDX) a promising investment pick.
- Zacks•12 days ago
QIAGEN's New Offerings to Broaden Hematology Testing Suite
QIAGEN (QGEN) continues to progress with test menu expansion.
- Zacks•13 days ago
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
Amedisys (AMED) continues to see impressive performance by Personal Care business. The company's focus on improving clinical quality buoys optimism.
